TRP_1170x120_3-8-19

John Hammergren

Brian Tyler becomes McKesson’s new CEO

Brian Tyler becomes McKesson’s new CEO

IRVING, Texas — Veteran McKesson leader, Brian Tyler, has become the company’s new chief executive officer Monday, succeeding John Hammergren. Hammergren has served as the company’s top executive since 1999. “I am incredibly humbled and grateful for the opportunity to lead this company,” said Brian Tyler, chief executive officer, McKesson Corp. “We have a seasoned and talented

McKesson joins World Cancer Day efforts

McKesson joins World Cancer Day efforts

SAN FRANCISCO — McKesson Corp. is supporting World Cancer Day by expanding its commitment to reduce the devastating impact of cancer by making medicines and treatment readily available and by supporting those on the frontlines. “Most Americans have been touched by cancer. We know that better cancer care is possible and McKesson is proud to play a part in making that

McKesson announces new global headquarters in Las Colinas, Texas

McKesson announces new global headquarters in Las Colinas, Texas

SAN FRANCISCO — McKesson Corp. has announced the relocation of its corporate headquarters from San Francisco, Calif. to Las Colinas, Texas, effective April 1, 2019, expanding upon its presence in the Dallas area. “We are excited to strengthen our presence in Texas and make Las Colinas our official global headquarters,” said John Hammergren, chairman and chief

McKesson’s Hammergren to retire, Tyler named CEO

McKesson’s Hammergren to retire, Tyler named CEO

SAN FRANCISCO — McKesson Corp. announced that John Hammergren, chairman and chief executive officer, has decided to retire, effective March 31, 2019. McKesson’s board of directors has unanimously selected Brian Tyler, currently president and chief operating officer, to succeed Hammergren as CEO, effective April 1, 2019. Tyler will also remain as president. Edward Mueller, currently

McKesson elects Caruso as independent director

McKesson elects Caruso as independent director

SAN FRANCISCO — McKesson Corp. announced that its board of directors has elected Dominic Caruso as a new independent director, effective September 12, 2018. With the election of Dominic Caruso, McKesson’s board of directors increases from eight to nine members, eight of whom are independent. “Dominic’s three decades of global financial and operational experience, leadership,

Dimos selected to oversee Health Mart for McKesson

SAN FRANCISCO — McKesson Corp. announced two key personnel moves, including the promotion of Chris Dimos to president of retail solutions for McKesson U.S. Pharmaceutical and Specialty Health. Dimos will now oversee the Health Mart pharmacy network, taking over from Steve Courtman, who left the company to join health insurer Cigna as senior vice president

Julian to retire from McKesson

SAN FRANCISCO — Paul Julian, executive vice president and group president at McKesson Corp., is slated to retire at the end of the year. Julian currently has senior operating responsibility for McKesson’s domestic and international Distribution Solutions businesses, including pharmaceutical distribution, medical-surgical distribution, specialty health and retail pharmacy systems and automation. As president of McKesson

McKesson buys RxCrossroads

SAN FRANCISCO — McKesson Corp. has agreed to buy RxCrossroads, a provider of tailored services to pharmaceutical and biotechnology manufacturers, from CVS Health. The deal, expected to close early next year, is valued at $735 million, or about $635 million net of the present value of incremental cash tax benefits. It will be funded by

McKesson to buy RxCrossroads from CVS for $735 million

McKesson to buy RxCrossroads from CVS for $735 million

SAN FRANCISCO — McKesson Corp. announced late Monday that it had signed a definitive agreement to purchase RxCrossroads, a provider of tailored services to pharmaceutical and biotechnology manufacturers, from CVS Health. The transaction is valued at $735 million, or approximately $635 million net of the present value ofincremental cash tax benefits, and will be funded by

Trump declares opioid abuse a public health emergency

Trump declares opioid abuse a public health emergency

WASHINGTON — Following through on pledge made this summer, President Donald Trump has formally declared the nation’s growing opioid abuse epidemic as a public health emergency. In a press conference at the White House on Thursday, the president and First Lady Melania Trump announced the action, which has drawn plaudits from public officials and pharmacy

McKesson CEO agrees opioid crisis is national emergency

McKesson CEO agrees opioid crisis is national emergency

SAN FRANCISCO — McKesson Corp. chairman and chief executive officer John Hammergren has endorsed President Donald Trump’s plan to designate the opioid abuse crisis as a national emergency. Trump this week is expected to formally declare the growing misuse and abuse of narcotic painkillers as a national emergency after saying this summer that he planned

McKesson steps up Hurricane Harvey support

McKesson steps up Hurricane Harvey support

SAN FRANCISCO — McKesson Corp. has boosted its Hurricane Harvey relief donations to more than $300,000 in support of recovery efforts in the inundated Houston area. McKesson and the McKesson Foundation late Thursday announced $100,000 cash donation to nonprofit Direct Relief and $150,000 in-kind donation of medical supplies to World Vision. The two organizations will

McKesson boosts Rx tech solutions with CoverMyMeds buy

McKesson boosts Rx tech solutions with CoverMyMeds buy

SAN FRANCISCO — McKesson Corp. is bolstering its pharmacy technology services with its $1.1 billion deal to acquire CoverMyMeds LLC from private equity firm Francisco Partners. Columbus, Ohio-based CoverMyMeds provides the nation’s largest electronic prior authorization (ePA) platform for medications. The company said its software suite automates the drug prior authorization process for more than

McKesson to pay $150 million in DEA, DOJ settlement

McKesson to pay $150 million in DEA, DOJ settlement

SAN FRANCISCO — McKesson Corp. has agreed to pay $150 million in a settlement with the Drug Enforcement Administration (DEA) and Department of Justice (DOJ) involving its monitoring and reporting of suspicious controlled substance orders. McKesson said late Tuesday that under the administrative and civil settlements the DEA will suspend the company’s DEA registrations to